Recombinant PDCD1 (Nivolumab Biosimilar) 抗体
适用: 人
FACS, in vivo
宿主: 小鼠
Monoclonal
5C4-B8
unconjugated
Recombinant Antibody
-
- 抗原 See all PDCD1 (Nivolumab Biosimilar) products
- PDCD1 (Nivolumab Biosimilar)
- 抗体类型
- Recombinant Antibody
- 适用
- 人
-
宿主
- 小鼠
-
克隆类型
- 单克隆
-
标记
- This PDCD1 (Nivolumab Biosimilar) antibody is un-conjugated
- 应用范围
- Flow Cytometry (FACS), In vivo Studies (in vivo)
- 原理
- Nivolumab Biosimilar, Human PD-1 Monoclonal Antibody
- 特异性
- The in vivo grade nivolumab biosimilar specifically binds to PD-1, antagonizing its interaction with its known ligands PD-L1 and PD-L2.
- 产品特性
- Recombinant Humanized IgG4 Monoclonal Antibody.
- 纯化方法
- Protein A affinity column
- 纯度
- > 95% by SDS-PAGE under reducing conditions and HPLC.
- 过滤
- 0.2 μm filtered
- 内毒素水平
- < 1 EU per 1 mg of the protein by the LAL method.
- 免疫原
- The anti-human programmed cell death protein 1 (PD-1) monoclonal antibody nivolumab biosimilar was produced in the nivolumab biosimilar CHO stable cell line.
- 克隆位点
- 5C4-B8
- 亚型
- IgG4 kappa
-
-
- 应用备注
- ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by nivolumab.
- 限制
- 仅限研究用
-
- 状态
- Liquid
- 浓度
- 1 mg/mL
- 缓冲液
- PBS, pH 7.4, no stabilizers or preservatives.
- 储存液
- Without preservative
- 注意事项
- Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 储存条件
- -20 °C
- 储存方法
- 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
- 有效期
- 12 months
-
- 抗原
- PDCD1 (Nivolumab Biosimilar)
- Abstract
- PDCD1 (Nivolumab Biosimilar) 产品
- 别名
- CD279 antibody, PD-1 antibody, PD1 antibody, SLEB2 antibody, hPD-1 antibody, hPD-l antibody, programmed cell death 1 antibody, PDCD1 antibody
- 物质类
- Biosimilar
- 背景
-
What is Nivolumab biosimilar research grade? Nivolumab is a humanized IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. Nivolumab Biosimilar uses the same protein sequences as the therapeutic antibody nivolumab.
PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1).
Nivolumab blocks PD-1 inhibitory signalling to T-cells. It has a long duration of action as it is administered every 2-4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion-related adverse effects, complications of allogenic hematopoietic stem cell transplants, embryo-fetal toxicity.
The ligands PD-L1 and PD-L2 bind to the PD-1 receptor on T-cells, inhibiting the action of these cells. Tumor cells express PD-L1 and PD-L2. Nivolumab binds to PD-1, preventing PD-L1 and PD-L2 from inhibiting the action of T-cells, restoring a patient's tumor-specific T-cell response.
-
You are here:
